158 related articles for article (PubMed ID: 38112103)
21. Long-Acting Growth Hormone Preparations and Their Use in Children with Growth Hormone Deficiency.
Pampanini V; Deodati A; Inzaghi E; Cianfarani S
Horm Res Paediatr; 2023; 96(6):553-559. PubMed ID: 35220308
[TBL] [Abstract][Full Text] [Related]
22. Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study.
Maniatis AK; Carakushansky M; Galcheva S; Prakasam G; Fox LA; Dankovcikova A; Loftus J; Palladino AA; de Los Angeles Resa M; Turich Taylor C; Dattani MT; Lebl J
J Endocr Soc; 2022 Oct; 6(10):bvac117. PubMed ID: 36101713
[TBL] [Abstract][Full Text] [Related]
23. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
[TBL] [Abstract][Full Text] [Related]
24. Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH.
Miller BS; Blair JC; Rasmussen MH; Maniatis A; Mori J; Böttcher V; Kim HS; Bang RB; Polak M; Horikawa R
J Clin Endocrinol Metab; 2023 Nov; 108(12):3090-3099. PubMed ID: 37406251
[TBL] [Abstract][Full Text] [Related]
25. Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial.
Miller BS; Blair JC; Rasmussen MH; Maniatis A; Kildemoes RJ; Mori J; Polak M; Bang RB; Böttcher V; Stagi S; Horikawa R
J Clin Endocrinol Metab; 2022 Nov; 107(12):3378-3388. PubMed ID: 36062966
[TBL] [Abstract][Full Text] [Related]
26. Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency.
Paton DM
Drugs Today (Barc); 2022 Oct; 58(10):509-517. PubMed ID: 36305544
[TBL] [Abstract][Full Text] [Related]
27. Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency.
Takahashi Y; Biller BMK; Fukuoka H; Ho KKY; Rasmussen MH; Nedjatian N; Sværke C; Yuen KCJ; Johannsson G
Pituitary; 2023 Feb; 26(1):57-72. PubMed ID: 36380045
[TBL] [Abstract][Full Text] [Related]
28. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Horikawa R; Juul RV; Saenger P;
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1847-61. PubMed ID: 31917835
[TBL] [Abstract][Full Text] [Related]
29. Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial.
Maniatis AK; Nadgir U; Saenger P; Reifschneider KL; Abuzzahab J; Deeb L; Fox LA; Woods KA; Song W; Mao M; Chessler SD; Komirenko AS; Shu AD; Casella SJ; Thornton PS
Horm Res Paediatr; 2022; 95(3):233-243. PubMed ID: 35263755
[TBL] [Abstract][Full Text] [Related]
30. Growth hormone therapy in adults with growth hormone deficiency: a critical assessment of the literature.
He X; Barkan AL
Pituitary; 2020 Jun; 23(3):294-306. PubMed ID: 32060708
[TBL] [Abstract][Full Text] [Related]
31. Adult growth hormone deficiency: clinical advances and approaches to improve adherence.
Yuen KCJ; Llahana S; Miller BS
Expert Rev Endocrinol Metab; 2019 Nov; 14(6):419-436. PubMed ID: 31721610
[No Abstract] [Full Text] [Related]
32. Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk.
Boguszewski CL
Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101817. PubMed ID: 37643936
[TBL] [Abstract][Full Text] [Related]
33. Impact of long-acting growth hormone replacement therapy in adult growth hormone deficiency: Comparison between adolescent, adult, and elderly patients.
Kargi AY
Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101825. PubMed ID: 37802712
[TBL] [Abstract][Full Text] [Related]
34. The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency.
Grumbach MM; Bin-Abbas BS; Kaplan SL
Horm Res; 1998; 49 Suppl 2():41-57. PubMed ID: 9730672
[TBL] [Abstract][Full Text] [Related]
35. Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3.
Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Röhrich S; Saenger P; Horikawa R
J Clin Endocrinol Metab; 2023 Sep; 108(10):2569-2578. PubMed ID: 36995872
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.
Juul RV; Rasmussen MH; Agersø H; Overgaard RV
Clin Pharmacokinet; 2019 Jan; 58(1):63-75. PubMed ID: 29671202
[TBL] [Abstract][Full Text] [Related]
37. Adherence, Attitudes and Beliefs of Growth Hormone Deficient Patients - A Questionnaire-based Cohort Study.
Amereller F; Schilbach K; Schopohl J; Störmann S
Exp Clin Endocrinol Diabetes; 2021 Feb; 129(2):112-117. PubMed ID: 31266067
[TBL] [Abstract][Full Text] [Related]
38. Long-acting recombinant human growth hormone in the treatment of pediatric growth hormone deficiency, how far have we got?
Bouhours-Nouet N; Teinturier C
Arch Pediatr; 2022 Feb; 28(8S1):8S14-8S20. PubMed ID: 37870528
[TBL] [Abstract][Full Text] [Related]
39. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
Thornton PS; Maniatis AK; Aghajanova E; Chertok E; Vlachopapadopoulou E; Lin Z; Song W; Christoffersen ED; Breinholt VM; Kovalenko T; Giorgadze E; Korpal-Szczyrska M; Hofman PL; Karpf DB; Shu AD; Beckert M
J Clin Endocrinol Metab; 2021 Oct; 106(11):3184-3195. PubMed ID: 34272849
[TBL] [Abstract][Full Text] [Related]
40. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
Johannsson G; Gordon MB; Højby Rasmussen M; Håkonsson IH; Karges W; Sværke C; Tahara S; Takano K; Biller BMK
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1358-76. PubMed ID: 32022863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
